-
Hims & Hers Health (NYSE:HIMS) announced a new partnership with Eli Lilly to offer Zepbound and Foundayo on its platform.
-
The agreement brings fully FDA-approved GLP-1 obesity drugs into the Hims & Hers telehealth ecosystem for eligible patients.
-
Patients will be able to complete consultations, receive prescriptions, and access these Eli Lilly treatments through Hims & Hers digital services.
-
The Lilly alliance for Zepbound and Foundayo is important. However, Hims & Hers Health has broader storylines investors should watch. Our analysis turns up 1 warning sign for Hims & Hers Health as well.
This obesity drug partnership highlights one fast-growing theme, but there are many other companies tied to similar demand drivers too. 52 AI infrastructure stocks .
Hims & Hers Health operates a consumer-focused telehealth platform that connects people with licensed clinicians across the US and several international markets. Integrating branded obesity drugs gives the business another regulated treatment option to plug into that existing virtual care network.
2 things going right for Hims & Hers Health that this headline doesn't cover.
What Eli Lilly's GLP 1 deal really shifts for the Hims & Hers Health story
This Lilly partnership plugs directly into the existing narrative around Hims & Hers Health leaning into higher complexity, recurring categories like branded GLP 1 weight loss. It pushes the business further toward being a front door for regulated obesity care instead of relying on compounded alternatives. This ties back to the catalyst that depends on converting weight loss interest into durable subscriber relationships. At the same time, it interacts with existing risks around regulatory scrutiny and margins because branded drugs at defined self pay prices, US$149 per month for Foundayo and US$299 per month for Zepbound, could influence both economics and how closely regulators watch the model.
See how these catalysts shape Hims & Hers Health's path to a $31.15 fair value .
From here, a practical marker to track is how many weight loss members Hims & Hers discloses through its GLP 1 programs in upcoming quarterly reports, especially relative to the 100,000 plus new monthly subscribers previously tied to its weight offerings. That comparison will show whether fully FDA approved drugs are reshaping the mix or primarily maintaining the current trajectory.
Add Hims & Hers Health to your Watchlist and get alerts as these catalysts play out.
This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include HIMS .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
